Friday, November 6, 2020
- 9:00AM-11:00AM
-
Abstract Number: 0304
Type I Interferon Inhibits Glucocorticoid-Induced Leucine Zipper (GILZ) Expression and Upregulation by Glucocorticoids
SLE – Etiology & Pathogenesis Poster- 9:00AM-11:00AM
-
Abstract Number: 0080
Understanding Ankylosing Spondylitis –
Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing- 9:00AM-11:00AM
-
Abstract Number: 0135
Understanding the Rheumatologist-Patient Relationship in Treating Rheumatoid Arthritis
Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA- 9:00AM-11:00AM
-
Abstract Number: 0209
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 Weeks
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0207
Upadacitinib Monotherapy in Methotrexate-naïve Patients with Rheumatoid Arthritis: Results at 72 Weeks
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0029
Urine Proteomic Classifiers Predict Renal Histological Activity and Chronicity Indices and May Predict Treatment Response in Lupus Nephritis
Genetics, Genomics & Proteomics Poster- 9:00AM-11:00AM
-
Abstract Number: 0105
Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Osteoporosis & Metabolic Bone Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 0160
Use of PROMIS29 Across Inflammatory Arthritis: Score Distributions and Impact of Contextual Factors
Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA- 9:00AM-11:00AM
-
Abstract Number: 0344
Use of the BASDAI in Psoriatic Arthritis Patients with and Without Axial Disease
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 0258
Using Patient-Reported Outcomes Measures to Classify Patients with Systemic Lupus Erythematous
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations- 9:00AM-11:00AM
-
Abstract Number: 0351
Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0170
Utilizing Design Thinking to Develop a Decision Aid for Patients with Psoriasis and Psoriatic Arthritis
Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA- 9:00AM-11:00AM
-
Abstract Number: 0161
Validation of Patient-reported Outcomes (PRO) Lung Questionnaires for Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at Risk for Lung Disease
Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA- 9:00AM-11:00AM
-
Abstract Number: 0427
Validation of Physician Global Assessment as an Outcome Measure in Relapsing Polychondritis